source
- Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancerThe DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
- Amgen and AbbVie report Inflation Reduction Act negotiations dent Q1 salesAmgen and AbbVie disclosed in their first-quarter earnings that the Inflation Reduction Act is already affecting their sales. The companies said the first set of drug-price negotiations required b…